Articles tagged with Cell Therapies
Researchers discuss the benefits of CAR-T therapy in treating B-cell lineage acute lymphoblastic leukemia (B-ALL) in children. The therapy, tisagenlecleucel, has shown promising results and is now priced at $508,250, a more manageable cost compared to other gene therapies.
A team of POSTECH and ImmunoBiome has discovered a dietary-derived bacterial strain, IMB001, that induces nutritional immunity and boosts anti-tumor responses. The strain works by skewing tumor-infiltrating macrophages toward an inflammatory phenotype, leading to increased cell death of rapidly multiplying tumor cells.
A new study shows that gene therapy delivered by nanocarriers can repair damaged discs and reduce signs of back pain in mice. The treatment, which uses naturally derived nanocarriers to deliver genetic material for a protein key to tissue development, restored structural integrity and function to degenerated discs.
A recent study reveals that a cellular process called transfer Ribonucleic acid (tRNA) modification influences the malaria parasite’s ability to develop resistance. This breakthrough discovery could help researchers develop new drugs to combat resistance and better tools for studying RNA modifications.
A new Dartmouth-led study has provided new insights into the therapeutic potential of bacteriophage therapy for treating diseases like cystic fibrosis. Researchers found that respiratory epithelial cells sense and respond to therapeutic phages, and interactions between phages and epithelial cells are heterogenous in nature.
University of Minnesota researchers found that immunotherapy improves CD8+ T-cell responses in older mice, reducing mortality from infections. The treatment, PD1 blockade, enhances the ability of T cells to kill harmful cells infected with a virus.
Researchers discuss therapeutic opportunities for hypermutated urothelial carcinomas that are resistant to immunotherapy, including the potential of targeted therapies. High TMB is associated with defects in mismatch repair proteins and can lead to increased sensitivity to cancer treatments.
Dana-Farber researchers discovered a molecular complex called PI3Kgamma that supports the survival of certain leukemia cells. The team found that eganelisib, an existing medicine, can inhibit this complex and has shown promise in animal models and clinical trials.
A late University of Virginia School of Medicine scientist's research on the SAS1B protein could lead to new cancer treatments for multiple cancers. The discovery has the potential to selectively target cancer cells while sparing healthy tissue.
A massive study identifies new biomarkers for renal cell carcinoma subtypes, improving diagnosis and treatment. The researchers' integrative analysis of proteogenomic datasets reveals molecular features shared by clear cell and non-clear cell RCC tumors, as well as unique features to various subtypes.
Researchers at the University of Trento have identified a collection of molecular tools to rewrite DNA, including a compact Cas9 enzyme from the human microbiome. The discovery has potential for gene therapy applications and could speed up the development of therapies for genetic diseases.
The Ottawa Hospital is receiving a $59 million grant to boost Canada's capacity for life-saving biotherapeutics, including vaccines, gene therapies, and cell therapies. The funding will support the construction and operation of a world-class biomanufacturing facility at its new campus.
A new study found extensive alternative splicing of messenger RNA in untreated multiple sclerosis patients compared to healthy controls. Interferon-ß therapy corrected dysregulated alternative splicing, linking it to future clinical exacerbations.
Researchers found PLS occurs significantly more frequently in unequal AB0 settings, leading to haemolysis and anaemia in patients. Blood group A patients with O transplants are particularly at risk.
A new therapy has been identified that can penetrate the slime protecting drug-resistant bacteria, allowing it to be killed by the body's immune system or antibiotics. The antimicrobial peptide, derived from cow peptides, targets sugar connections in the slime structure, damaging its integrity and allowing entry.
Researchers at the University of Notre Dame found that adding a pre-ketone supplement to an immunotherapy treatment significantly reduced prostate cancer in laboratory settings. The combination therapy made tumors sensitive to immunotherapy, leading to 23% tumor cure rates and dramatic shrinking.
Researchers at the University of Leipzig Medical Center have identified biomarkers associated with the response to CAR T cell therapy in multiple myeloma. These biomarkers enable patients to predict their likelihood of responding well or less well to treatment before initiating therapy.
Researchers identified elevated MALAT1 levels in various blood cancers, correlating with adverse outcomes. MALAT1 promotes cancer cell proliferation, migration, invasion, and metastasis through multiple mechanisms.
Researchers at Baylor College of Medicine conducted a phase I clinical trial using CAR T cells engineered to target the HER2 protein, which is overexpressed on sarcoma cells. The therapy showed safety and associated with clinical benefit, with improved CAR T expansion and persistence.
Researchers developed a gene-based therapy that restored typical cellular function in organoids created from cells of people with Timothy syndrome. The treatment used antisense oligonucleotides to decrease the use of mutated exon 8A and increase reliance on non-affected exon 8, restoring normal calcium channel functioning.
Researchers at TUM have uncovered a mechanism by which tumor cells prevent the formation of immune responses, including cytotoxic T cells. This discovery provides rationales for new cancer immunotherapies and could enhance existing treatments.
Therapeutic phages can detect epithelial cells of the human respiratory tract, eliciting proinflammatory responses. Specific phage properties and airway microenvironment influence these responses.
Researchers at NJIT are developing a hydrogel therapy that prevents viruses like SARS-CoV-2 from attaching to and entering cells. The peptides in the gel form a 'molecular mask' that muffles the virus's action, providing a potential first line of defense against biological threats.
Researchers have identified CAR-T cell therapy as a potential treatment for autoimmune diseases such as rheumatoid arthritis, SLE, and type 1 Diabetes Mellitus. Early studies have shown promising results in reducing disease activity and improving patients' quality of life, but long-term data on safety and efficacy is limited.
Scientists have identified a consistent signature of multiple sclerosis in the blood of patients years before they develop symptoms. The discovery, published in Nature Medicine, could lead to earlier diagnosis and treatment of the disease, affecting nearly 1 million people in the US.
Scientists at Salk Institute explore the clinical potential of cannabinol (CBN) in treating traumatic brain injury, Alzheimer's disease, and Parkinson's disease. They identify four CBN analogs with improved neuroprotective ability and drug-like efficacy.
A new study supports the use of neoadjuvant chemohormonal therapy for patients with locally advanced prostate cancer, showing improved biochemical progression-free survival and treatment-free survival rates. The treatment combination offers significant benefits in controlling PSA levels and potentially improving patient outcomes.
Researchers developed novel therapeutic bispecific antibodies targeting IgM and B-cell surface antigens, which directly inhibited cell proliferation via cell-cycle arrest and apoptosis in vitro. These findings suggest that anti-IgM/B-cell surface antigen-binding specific antibodies are promising therapeutic agents for B-cell malignancies.
Researchers at the University of Pittsburgh have discovered how to overcome resistance to conventional immunotherapies in metastatic uveal melanoma. They developed a clinical tool called Uveal Melanoma Immunogenic Score (UMIS) to predict patient response and improve treatment outcomes.
Scientists at CNIC have identified mechanisms by which anthracyclines damage the hearts of cancer patients, leading to cardiac injury. The study suggests that a protein-enriched diet may prevent muscle atrophy caused by anthracycline chemotherapy.
New findings in The American Journal of Pathology indicate that periostin promotes esophageal squamous cell carcinoma progression by enhancing cancer and stromal cell migration in cancer-associated fibroblasts. Periostin may be a promising therapeutic target for treating ESCC.
Researchers identified a gene mutation associated with impaired natural killer cell function, leading to increased susceptibility to viral infections in people with a rare genetic condition. Oleic acid supplementation shows promise as a potential therapy for these patients.
MD Anderson researchers presented studies on combination therapies for AML and lung cancer, tumor microbiomes in immunity, and improved HPV screening. Genetic markers predict extended survival with KRAS inhibitors and may identify patients who benefit from novel combinations.
Two anti-inflammatory molecules, TGFβ1 and HpTGM, reduce the inflammatory response within the injured heart and scarring. Treatment with these proteins at the time of reperfusion reduces infarct size and mature scar size.
Researchers at the University of Cincinnati Cancer Center presented abstracts on new potential drugs and targets for treating various types of cancer. A study found that a brain-permeable drug called AM-101 sensitizes brain metastatic tumors to radiation, improving survival in preclinical animal models.
Researchers at Johns Hopkins Kimmel Cancer Center have developed a novel antibody-drug conjugate (ADC) therapy that effectively kills T-cell cancers in mice with human T-cell tumors. The treatment targets TRBC1 protein expressed on the surface of cancer cells while preserving normal T cells.
A second-generation melanoma vaccine has shown improved survival rates for male patients compared to female patients, particularly those who are younger and have earlier-stage cancer. The vaccine targets helper T cells to recognize melanoma proteins, leading to boosted patient survival and reduced cancer reoccurrences.
Researchers outline ferroptosis mechanisms and regulatory networks in lung cancer, highlighting potential therapeutic targets. The study suggests ferroptosis as a novel approach to overcome treatment resistance in lung cancer, providing hope for improving clinical outcomes.
Researchers unveil innovative strategies to overcome metabolic constraints in CAR-T cell therapy, aiming to boost its efficacy in treating solid tumors. Metabolic interventions targeting immunosuppressive metabolites, metabolite uptake, and mitochondrial metabolism are proposed to enhance anti-tumor activity.
A team of researchers at Weill Cornell Medicine has discovered a critical protein sensor called SEL1L that regulates collagen clearance from tissue. This finding provides new insights into the development of therapeutic strategies for diseases like lung fibrosis, which currently have no effective treatments.
A new analysis by researchers from Penn Medicine found that minority patients with lymphoma may be less likely to receive CAR T cell therapy due to clinical, provider, and socioeconomic barriers. The study assessed data from two cancer centers and found significant disparities in treatment access among minority populations.
A new study found that a viral infection can cause cognitive impairments by damaging the blood-brain barrier, leading to memory loss and learning difficulties. Researchers developed a gene therapy that stimulated the Wnt/beta-catenin pathway to prevent this damage and improve cognitive function in mice infected with SARS-CoV-2.
Researchers have discovered a new immunotherapy approach to overcome resistant leukemia by targeting the mutated TP53 gene. Combining pharmacological therapies with genetically engineered CAR T-cells increases effectiveness against cancer cells, offering promising strategies for patients with resistant disease.
Researchers developed a unique microfluidics-based diagnostic system that combines optical tweezers with stimulated Raman spectroscopy to enable fast and accurate diagnosis of leukemia. The device can identify cancer cells based on their metabolic activities and metabolites, providing tailored treatment options.
NeXT Personal assay detects up to ~1,800 somatic variants specific to the patient's tumor with a detection threshold of 1.67 PPM and 99.9% specificity. The assay showed linearity over a range of 0.8 to 300,000 PPM.
Researchers have demonstrated that attaching 'empty' backpacks to neutrophils activates them against cancer. The treated neutrophils infused into mice with cancer activated other immune cells and reduced tumor size. This technique is attractive as a 'drug-free' cell therapy for cancer.
A combination of short-course hormonal therapy and stereotactic body radiation therapy has been shown to be safe and effective in treating metastatic prostate cancer. In a preliminary study, 50% of patients remained recurrence-free six months after treatment, with less than a quarter experiencing severe side effects.
A study by UNC researchers found that a metabolic enzyme called Acetyl-CoA Carboxylase (ACC) causes T cells to store fat rather than burning it for energy in solid tumors. Inhibiting ACC expression allowed T cells to persist better in tumors, leading to potential breakthroughs in immunotherapies like CAR T-cell therapies.
Researchers have made progress in understanding atherosclerosis, identifying potential new approaches for early detection and therapy. The study found that TREM2 regulates the activity of macrophages, playing an important role in forming unstable plaques that increase heart attack and stroke risk.
Researchers at Johns Hopkins Medicine have developed a novel approach to target group 3 medulloblastoma tumors in mice, reducing tumor growth by 40-50% and extending survival by up to 84 days. The therapy uses antisense oligonucleotides to block lnc-HLX-2-7 from binding to the HLX promoter region.
Researchers at Mass General Cancer Center have achieved dramatic tumor regression in glioblastoma patients after receiving next generation CAR-T therapy. The treatment, known as INCIPIENT, combines two forms of therapy to target mixed cell populations within tumors.
Kobe University scientists develop material guideline for high-efficiency PV cells, OLED displays and anti-cancer therapies by understanding energy transfer between molecules. The research enables aligned electron spin states to combine low-energy photons into a high-energy photon.
Early trial results from six patients with recurrent glioblastoma show reduced tumor sizes after administering dual-target CAR T cells targeting EGFR and IL13Rα2 intrathecally. This 'dual-target' approach may outsmart the defense systems of GBM, leading to more effective therapies.
Scientists from the University of Cologne developed threofuranosyl nucleic acid (TNA) with a new base pair, offering improved stability and function compared to natural DNA and RNA. This breakthrough could enable targeted drug delivery, diagnostics, and recognition of viral proteins or biomarkers.
Researchers at the University of Cincinnati Cancer Center have identified a new protein called p47 that helps prevent breast cancer metastasis. The study found that lower p47 expression was correlated with higher breast cancer metastasis, and that increasing p47 function could potentially lead to new therapies.
Researchers discovered GZ17-6.02's ability to interact with proteasome inhibitors in a greater than additive fashion to kill multiple myeloma cells and alone inhibit inhibitor-resistant cells. The compound combination also activated key pathways and increased autophagosome formation, leading to tumor cell killing.
Researchers at MIT discovered that daily exposure to light and sound with a frequency of 40 hertz protects brain cells from chemotherapy-induced damage, preventing memory loss and improving cognitive functions. The treatment also helped prevent DNA damage, inflammation, and promoted the growth of oligodendrocytes, the cells responsible...
Researchers have designed a candidate drug to target the K-Ras G12D mutation, responsible for nearly half of all pancreatic cancer cases. The molecule permanently modifies the mutation, stopping tumor growth in cancer cell lines and animal models.
UCSF scientists discover delivering therapeutic molecules to amniotic fluid can effectively treat Angelman syndrome and other neurological conditions. The treatment uses antisense oligonucleotides, which can alter gene expression, and has shown improved motor function and learning outcomes in mice.
Researchers investigated combining Sacituzumab govitecan with platinum-based chemotherapeutics for triple-negative breast cancer, urinary bladder carcinoma, and small-cell lung carcinoma. The study showed additive to synergistic antitumor effects in vitro and in vivo, with improved outcomes in tumor-bearing animals.